World Journal of
Pharmaceutical and Life Sciences

GALECTIN 3: NEW MARKER FOR MONITORING CLINICAL HEART FAILURE

Julia San Miguel Rodríguez*, Julita Rodríguez Barbero, Angel San Miguel Hernández, Angel San Miguel Rodríguez and María San Miguel Rodríguez

ABSTRACT

Introduction: Galectin-3 is a structurally unique member of a family of multifunctional beta-galactoside-binding lectins that are important in the regulation of inflammation, immunity, and cancer. Goals. A study has been carried out in 36 apparently healthy patients without known heart disease and in 52 patients who mainly suffered from heart failure (HF). Material and methods: Patient samples have been processed with a chemiluminescent immunoassay (CMIA) (Abbott Diagnostics) on an Architect. The assay is based on two monoclonal antibodies (87B5 and M3 / 38) specific for galectin-3. The increase in galectin-3 has been associated with fibroblast proliferation, a key component in the establishment of cardiac restructuring. The determination of BNP and cardiac troponin I was carried out on a Univel Dxi600 autoanalyzer (Beckman Coulter). Results: The mean levels of galectin-3 obtained in the group of healthy patients was 25.3±17.3 ng / ml, while the mean levels of the 52 patients with chronic heart failure was 27.9±24.8 ng /ml. While the mean levels of BNP in the group of healthy patients was 91.4±71.7 pg /ml, while the mean levels of the 52 patients with chronic heart failure 257.3±195.8 pg /ml. And the mean values of Troponin I in the group of healthy patients was 0.031 ± 0.026 ng /ml, and in the group of patients with HF it was 0.043 ± 0.037 ng / ml. Conclusions: We found statistically significant differences when comparing the mean levels of galectin-3 in the group of healthy patients with those with chronic heart failure (p <0.05) and also in the mean BNP values compared to the group with chronic HF (p < 0.05). The different studies carried out on galectin-3 show that the concentrations are useful in a large number of cardiovascular diseases. The majority to evaluate the investigation of the correlation with other risk factors and the prognostic utility in different clinical endpoints in patients with chronic HF. Studies have been carried out in patients with acute decompensated HF, acute coronary artery disease, and healthy populations. In all of them, galectin-3 showed a prognostic utility for mortality, the development of chronic HF, the development of cardiovascular diseases, or rehospitalization.

[Full Text Article]   [Download Certificate]